Genetic testing, simplified

The answers you need,
easily and affordably

Start an order
  • Guidelines now recommend genetic testing for all metastatic prostate cancer patients. Learn more.
  • We now offer CancerGene Connect, one of the most efficient tools for managing family histories. Learn more.
  • Join us Nov. 8 or view the recording: Learn about Invitae’s approach to variant classification. Register to view.

Explore our genetic test catalog

Simplicity. Breadth. Confidence.

A carefully designed menu of tests to address your patients’ needs in hereditary cancer, cardiology, neurology, pediatric genetics, rare diseases, and more

view catalog

Robust clinical evidence generated with leading institutions

  • The only clinical lab to deliver a >1000 patient study demonstrating excellent analytical validity and concordance with traditional testing methods
  • Multiple studies conducted in collaboration with world-renowned medical centers
View studies
 

Let’s save the healthcare system valuable dollars, together

With Invitae, you’re part of the solution.

Medically responsible testing—the right tests for the right patients

Transparent pricing.
Ethical billing.

 

Fast, customizable panel testing

Broad test menu

Select curated panels from Invitae’s comprehensive menu, or design your own panel at no additional charge.

Need more answers?

Re-requisition additional genes within the original clinical area at no additional charge within 90 days.

Quick turnaround

Results available in 10–21 calendar days (14 days on average).

A genetic diagnosis can affect an entire family


Only a small percentage of relatives pursue genetic testing after a disease-causing variant is found in their family, even though guidelines recommend it.1-3

Invitae now offers testing for all panels to first-degree family members at no additional charge* to help inform and empower more families.

 

LEARN MORE

*Order must be placed within 90 days of the original report

1. Christiaans I, et al. Update of genetic counseling and predictive DNA testing in hypertrophic cardiomyopathy. Eur J Hum Genet. 2008;16(10):1201-7.
2. Sharaf RN, et al. Uptake of genetic testing by relatives of Lynch syndrome probands: A systematic review. Clin Gastroenterol Hepatol. 2013;11(9):1093-100.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast and Ovarian V.2.2017. © National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed September 25, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org.  NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Now offering exome testing

Learn more